Evolution of the Average Target: DSM-Firmenich

Evolution of the Target Price: DSM-Firmenich

Changes in Analyst Recommendations: DSM-Firmenich

d64daa19.p8rF6X5tgzzThnjh3tRvBxYnhGAxNByIEu2xnIUeAn8.kvL0pwpez0yU6zHSlPkrfUcS7k1rUyvHeNj3q-hQVUzqoqzQKxfURrneQA~cd1186eb601d5c6544f558df4d04f60f
06-19 AlphaValue/Baader Europe Downgrades DSM-Firmenich to Reduce, Lifts PT MT
06-09 AlphaValue/Baader Europe Upgrades DSM-Firmenich to Add, Lifts PT MT
06-08 Goldman Sachs Downgrades DSM-Firmenich to Sell, Cuts PT MT
05-22 AlphaValue/Baader Europe Downgrades DSM-Firmenich to Reduce, Lifts PT MT
05-22 Swiss stocks - Factors to watch on May 22 RE
05-06 DSM-Firmenich: Volumes deliver, margin to follow Alphavalue
04-28 KBC Securities weighs in on DSM-Firmenich divestment Zonebourse
03-18 KBC Securities Still Positive on DSM-Firmenich Zonebourse
03-17 Sulfur and methanol prices soar on Middle East conflict Alphavalue
03-13 DSM-Firmenich ready to step up the pace and hit its mid-term targets Zonebourse
03-12 DSM-Firmenich: The story moves from restructuring to delivery Alphavalue
03-11 Kempen Downgrades DSM-Firmenich to Neutral, Cuts PT MT
03-04 Middle East tensions intensify pessimism in chemicals Alphavalue
02-26 AlphaValue/Baader Europe Adjusts Rating, Estimates for DSM-Firmenich on Sale of Animal Nutrition, Health Unit MT
02-25 DSM-Firmenich: ANH Divestment at a Discount May Unlock Growth Potential Alphavalue
02-13 Kepler Cheuvreux Downgrades DSM-Firmenich to Hold, Cuts PT MT
02-12 DSM-Firmenich: Profitability disappoints in FY25 Alphavalue
02-09 DSM-FIRMENICH : Jefferies reaffirms its Buy rating ZD
12-30 Berenberg Reduces DSM-Firmenich PT, Keeps Buy Rating MT
12-30 Berenberg Expects DSM-Firmenich to Retain Minority Stake in Vitamins Business Amid 'Protracted' Deal Talks MT
11-13 Barclays Downgrades DSM-Firmenich to Equalweight, Cuts PT MT
11-11 Goldman Sachs Downgrades DSM-Firmenich to Neutral, Cuts PT MT
25-10-30 DSM-Firmenich: From energy to fatigue: DSM-Firmenich's soft Q3 Alphavalue
25-10-22 AlphaValue/Baader Europe Revises DSM-Firmenich's Price Target Amid 'More Conservative' Outlook MT
25-10-20 DSM-Firmenich: Adopting a more conservative outlook in updated forecast assumptions Alphavalue

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+2.97%
+25.69%
+9.49%
+2.85%
+42.1%
+18.66%
+10.58%
+22.01%
Average +16.79%
Weighted average by Cap. +8.37%
See all sector consensus

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
20
Last Close Price
85.56EUR
Average target price
83.02EUR
Spread / Average Target
-2.97%
High Price Target
103.00EUR
Spread / Highest target
+20.38%
Low Price Target
60.00EUR
Spread / Lowest Target
-29.87%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

AlphaValue/Baader Europe
Goldman Sachs
alphavalue Théodore Duval-Segard
Kempen
Kepler Cheuvreux
JEFFERIES Chris Counihan
Berenberg Bank
Barclays
Deutsche Bank Research
BNP Paribas
Stifel Nicolaus
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
20
Last Close Price
85.56EUR
Average target price
83.02EUR
Spread / Average Target
-2.97%

Quarterly revenue - Rate of surprise